EUVIMEDEUVIMED entdecken
Open Access

Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)‐like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations

Ruixin Li iD, Yiyi Yao iD, Donglin Yang, Liping Mao, Yinjun Lou, Yi He, Haitao Meng, Wenjuan Yu, Aiming Pang iD, Sizhou Feng, Hongyan Tong, Mingzhe Han und 4 weitere

British Journal of Haematology · 2026-08 · 209 (2) · 642-652

DOI: 10.1111/bjh.70593 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 02.06.2026. Verfasst von Ruixin Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, fms-Like Tyrosine Kinase 3, Nuclear Proteins, Mutation. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Leukemia Precision Diagnosis and Treatment Innovation Platform, National Key R&D Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukaemia (AML) patients with concurrent FMS‐like tyrosine kinase 3 internal tandem duplication ( FLT3‐ ITD ), nucleophosmin 1 ( NPM1 ) and DNA methyltransferase 3 alpha ( DNMT3A ) mutations exhibit heterogeneous treatment outcomes. To identify optimal strategies for this subset, we retrospectively analysed 2541 AML patients with next‐generation sequencing from 2016 to 2023. Among them, 113 harboured triple mutations and had treatment outcomes: 79 received allogeneic haematopoietic stem cell transplantation (allo‐HSCT), and 34 underwent continuous chemotherapy (CMT). Compared with CMT, allo‐HSCT was associated with superior 2‐year overall survival (OS) (62.2% vs. 17.8%, p < 0.001). However, no clear additional benefit from allo‐HSCT was observed in patients who achieved composite complete remission (CRc) with DNMT3A measurable residual disease (MRD) negativity or complete remission with negative multiparameter flow cytometry MRD after the first cycle of CMT (CMT 1st ). Among patients who underwent allo‐HSCT, those in CRc after CMT 1st had significantly improved post‐transplant 2‐year OS (71.9% vs. 44.1%, p = 0.028), leukaemia‐free survival (65.4% vs. 40.2%, p = 0.029) and non‐relapse mortality (17.4% vs. 40.4%, p = 0.037). CRc rates were higher with venetoclax‐based intensive (88.2%) or non‐intensive (63.6%) CMT than with CMT alone ( p = 0.001). In conclusion, this study offers a potential treatment paradigm for AML patients with co‐occurring FLT3‐ ITD, NPM1 and DNMT3A mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, Acutefms-Like Tyrosine Kinase 3Nuclear ProteinsMutationHematopoietic Stem Cell TransplantationDNA (Cytosine-5-)-MethyltransferasesNucleophosminHumansFemaleDNA Methyltransferase 3AMaleAdultMiddle AgedRetrospective StudiesAdolescentAgedYoung AdultTransplantation, HomologousTandem Repeat SequencesAnimals

Stichwörter der Autor:innen

DNMT3ANPM1FLT3‐ITDtransplantation timingtreatment strategy

Substanzen

NucleophosminNPM1 protein, humanfms-Like Tyrosine Kinase 3DNA Methyltransferase 3ANuclear ProteinsDNA (Cytosine-5-)-MethyltransferasesFLT3 protein, humanDNMT3A protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
  • Tianjin Institutes of Health Science, Tianjin, China.
  • Hematopoietic Stem Cell Transplantation Center, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China.
  • Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, China.

ORCID-Profile: Ruixin Li, Yiyi Yao, Aiming Pang, Jie Jin, Meiwen Tang, Erlie Jiang, Huafeng Wang

Förderung

  • Leukemia Precision Diagnosis and Treatment Innovation Platform
  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • CAMS Innovation Fund for Medical Sciences, CIFMS
  • Key Research and Development Program of Zhejiang Province, China
  • National Key Research and Development Program of China
  • Key Research and Development Program of Zhejiang Province

Zitieren

APA

Li, R., Yao, Y., Yang, D., Mao, L., Lou, Y., He, Y., Meng, H., Yu, W., Pang, A., Feng, S., Tong, H., Han, M., Jin, J., Tang, M., Jiang, E., & Wang, H. (2026). Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)‐like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations. British Journal of Haematology, 209(2), 642-652. https://doi.org/10.1111/bjh.70593

Vancouver

Li R, Yao Y, Yang D, Mao L, Lou Y, He Y, et al. Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)‐like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations. British Journal of Haematology. 2026;209(2):642-652. doi:10.1111/bjh.70593

BibTeX
@article{Li2026,
  author = {Li, Ruixin and Yao, Yiyi and Yang, Donglin and Mao, Liping and Lou, Yinjun and He, Yi and Meng, Haitao and Yu, Wenjuan and Pang, Aiming and Feng, Sizhou and Tong, Hongyan and Han, Mingzhe and Jin, Jie and Tang, Meiwen and Jiang, Erlie and Wang, Huafeng},
  title = {Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)‐like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {209},
  number = {2},
  pages = {642--652},
  doi = {10.1111/bjh.70593}
}
Kostenlos starten →